评估IDB-011的安全性,耐受性和药代动力学的研究
一项随机,双盲,安慰剂控制的研究,以评估健康成人中IDB-011(IDB-774+IDB-898)的安全耐受性和药代动力学
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
研究概览
地位
条件
详细说明
This is a randomized, double blind, placebo-controlled, dose escalation, first-in-human, Phase I clinical trial to assess the safety, tolerability, PK and immunogenicity of IDB-011 in healthy volunteers aged 18-64. IDB-011 is comprised of IDB-774 and IDB-898, which will be administered as separate, consecutive intramuscular injections.
Volunteers will be recruited into sequential dosing cohorts. Within each cohort, eligible volunteers will be randomly allocated (6:2) to receive either IDB-011 or placebo (0.9% normal saline). A sentinel dosing scheme will be employed for the first 2 volunteers in each dosing cohort.
Volunteers will stay in a clinical research unit for up to 4 consecutive days and be followed for up to 1 year.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Cypress、California、美国、90630
- Altasciences Clinical Los Angeles
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy male or female
- Body mass index (BMI) within 18.0 kg/m2 to 30.0 kg/m^2, inclusively
- Female participants must not be pregnant, breastfeeding or intend to become pregnant through 1 year post-administration
- Male subjects must agree to not cause pregnancy or donate sperm for 1 year post-administration
- Non-smoker
- Agree to abstain from alcohol for 72 hours and caffeine for 48 hours prior to administration and during the confinement period
- Agree to not donate blood or plasma during study participation
- Agree not to travel to Rift Valley fever virus (RVFV) endemic areas during participation
Exclusion Criteria:
- Known history of RVFV infection
- Previous receipt of RVFV vaccine
- Illness with fever within 5 days prior to administration
- History of malignancy within prior 5 years
- History of significant cardiovascular, pulmonary, gastrointestinal, liver, kidney, hematologic, neurological, psychiatric, endocrine, immunologic, dermatologic disease
- History of hypersensitivity reaction
- History or clinical evidence of alcohol abuse
- Human immunodeficiency virus (HIV) positive
- Hepatitis C virus positive
- Hepatitis B virus positive
- Received immunoglobulin or antibody product within 6 months of administration
- Vaccine within 28 days of administration
- Received investigational agent within 3 months or < 5 half-lives (whichever is longer) prior to administration
- Donation of plasma, 1 unit or > 500 mL blood donation in 56 days prior to administration
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental: IDB-011 Cohort 1
IDB-011 dose level 1 |
IDB-774 + IDB-898 |
|
实验性的:Experimental: IDB-011 Cohort 2
IDB-011 dose level 2 |
IDB-774 + IDB-898 |
|
实验性的:Experimental: IDB-011 Cohort 3
IDB-011 dose level 3 |
IDB-774 + IDB-898 |
|
实验性的:Experimental: IDB-011 Cohort 4
IDB-011 dose level 4 |
IDB-774 + IDB-898 |
|
实验性的:Experimental: IDB-011 Cohort 5
IDB-011 dose level 5 |
IDB-774 + IDB-898 |
|
安慰剂比较:Comparator: Placebo
Normal saline |
Normal saline |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluation of safety and tolerability
大体时间:Through 1 year from administration
|
Safety to be measured via occurrence and severity of adverse events |
Through 1 year from administration
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Characterize pharmacokinetic profile
大体时间:Through 1 year from administration
|
Concentration in serum over time |
Through 1 year from administration
|
|
Evaluate immunogenicity
大体时间:Through 1 year from administration
|
Measurement of IDB-011 neutralizing antibodies in serum |
Through 1 year from administration
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.